Breathtec BioMedical CTO Delivers Presentation to
International Science Community
-Company exec updates breath analysis progress, and chairs
related session at prestigious event
VANCOUVER, BRITISH COLUMBIA March 17, 2017 -- InvestorsHub
NewsWire -- Breathtec BioMedical, Inc.
(CSE: BTH.CN) (CNSX: BTH)
(CSE: BTH) (XFRA: BTI) (OTCQB:
BTHCF) (the Company or
Breathtec), a medical diagnostics company focused
on developing, in-licensing and commercializing proprietary,
innovative and best-in-class breath analysis devices for the early
detection of infectious and life threatening diseases is pleased to
report that the Companys previously announced invitation to speak
at the 2017 Pittsburgh Conference on Analytical Chemistry and
Applied Spectroscopy (PittCon) was a notable success.
Breathtecs Chief Technology Officer, Dr. Michael Costanzo
traveled to the annual conference held in Chicago, Illinois where
he gave a well-received presentation on FAIMS technology, in
addition to presiding over the session in which he spoke, entitled
Metabolomics: Breath as a Sample for Clinical Analysis. A copy of
Dr. Costanzos presentation, Towards Point-of-Care Diagnostic
Screening for Breath Analysis Utilizing FAIMS and FAIMS/MS, is
available for review on the company website at: http://breathtecbiomedical.com/news/presentations/.
Breathtec recently announced the excellent progress being made
in our FAIMS device development along with the regulatory and
clinical path and timeline to market for the FAIMS technology. We
are pleased with the progress our team has made over the past 6
months since our last public presentation on this work and are
encouraged by the advancement of the design and the devices
capabilities, said Dr. Costanzo. The continued development and
foreseeable clinical benefit of a portable screening device has
garnered overwhelmingly positive feedback from our peers and
practitioners in the health care community.
PittCon was attended by nearly 13,000 conferees and exhibitors
who specialize or provide products and services in the field of
analytical chemistry. It holds one of the largest expos of its kind
in the world, with attendees traveling in from over 80 countries.
Presenting at PittCon provides critical feedback from experts and
nonexperts alike, as well as invaluable networking opportunities
with some of the largest service providers and manufacturers in the
chemical detection field.
Dr. Costanzo concluded his talk at PittCon with a discussion on
the unmistakable need for a clinical device capable of
differentiating between viral and bacterial respiratory infections
in a quick and noninvasive manner and the impact it could have on
the unnecessary use of antibiotics. Thus, we are excited to report
that our initial area of study for the FAIMS device will focus on
respiratory disease and infection. Notable applications include
viral vs bacterial infection, hospital-borne infections, and
communicable diseases that pose a risk to public health. With this
news, we would also like to announce a new research agreement with
ZeptoMetrix Corporation (ZMC), based out of Buffalo, NY. ZMC is an
industry leader and innovator in infectious disease diagnostic
development. Furthermore, ZMC offers a variety of custom diagnostic product
development including Virology, Bacteriology, Molecular, and
Immunology services.
ON BEHALF OF THE BOARD
Guy LaTorre
CEO & Director
For further information, please contact:
Kal Malhi
President & Director
Breathtec BioMedical, Inc.
Tel: +1 (352) 327-3152
info@breathtechbiomedical.com
investors@breathtecbiomedical.com
www.breathtecbiomedical.com
ABOUT PITTCON
Pittcon is the worlds leading annual conference and exposition
on laboratory science. Pittcon attracts attendees from industry,
academia and government from over 90 countries worldwide. The event
targets all laboratory scientists anyone who identifies,
quantifies, analyzes or tests the chemical or biological properties
of compounds or molecules, or who manages these laboratory
scientists. Having grown beyond its roots in analytical chemistry
and spectroscopy, Pittcon has evolved into an event that now also
serves a diverse constituency encompassing life sciences,
pharmaceutical discovery and QA, food safety, environmental,
bioterrorism and other emerging markets. Visit: http://pittcon.org
ABOUT BREATHTEC BIOMEDICAL INC. (CSE: BTH)
(OTCQB:
BTHCF)
Breathtec Biomedical, Inc. (Breathtec) was formed to propel
innovative research in the area of breath analysis as a medical
screening tool. Our efforts are aimed at leading the development of
commercially viable methods for the early screening of certain
diseases. Our primary avenue of investigation is focused on
innovation and advances in the field of specialized mass
spectrometry. For more information: www.breathtecbiomedical.com.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has
reviewed nor accepts responsibility for the adequacy or accuracy of
the content of this news release. This news release contains
forward-looking statements relating to product development,
licensing, commercialization and regulatory compliance issues and
other statements that are not historical facts. Forward-looking
statements are often identified by terms such as will, may, should,
anticipate, expects and similar expressions. All statements other
than statements of historical fact, included in this release are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Important
factors that could cause actual results to differ materially from
the Companys expectations include the failure to satisfy the
conditions of the relevant securities exchange(s) and other risks
detailed from time to time in the filings made by the Company with
securities regulations. The reader is cautioned that assumptions
used in the preparation of any forward-looking information may
prove to be incorrect. Events or circumstances may cause actual
results to differ materially from those predicted, as a result of
numerous known and unknown risks, uncertainties, and other factors,
many of which are beyond the control of the Company. The reader is
cautioned not to place undue reliance on any forward-looking
information. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made
as of the date of this news release and the Company will update or
revise publicly any of the included forward-looking statements as
expressly required by applicable law.